Page 3 - Rheumatology Research News Today : Breaking News, Live Updates & Top Stories | Vimarsana

FDA Approves Secukinumab as First Intravenous Interleukin-17A Antagonist for Rheumatic Diseases

The intravenous formulation of secukinumab is administered in monthly 30-minute, weight-based dosing and requires no pre-medication or lab monitoring.

United statesUniversity of washingtonChristy siegelPhilipj measeSwedish medical centerRheumatology researchUniversity of washington school medicineWashington schoolPsoriasis areaSeverity index

FDA approves Novartis (NVS) Cosentyx® as first intravenous (IV) formulation interleukin-17A antagonist for rheumatic diseases

FDA approves Novartis (NVS) Cosentyx® as first intravenous (IV) formulation interleukin-17A antagonist for rheumatic diseases
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Philipj measeChristy siegelRheumatology researchSwedish medical centerDrug administrationUniversity of washington school medicineClinical professorWashington schoolVice president

FDA approves Novartis Cosentyx® as first intravenous (IV) formulation interleukin-17A antagonist for rheumatic diseases

FDA approves Novartis Cosentyx® as first intravenous (IV) formulation interleukin-17A antagonist for rheumatic diseases
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesPhilipj measeEli lillyMarlena abdinoorMichael meoPrnewswire novartisActa derm venereolSloan simpsonChristy siegelJulie masowDermatol venereolNovartis cosentyxDrug administrationRheumatology researchBausch healthNovartis pharmaceuticals corp

Lupus Nephritis: Hopes, Questions Arise for Baricitinib

Results from a small, independently funded, double-blind, active-comparator trial suggest that baricitinib could be beneficial in the treatment of lupus nephritis.

United statesSouth australiaEricf morandManal hassanienEli lillyEuropean alliance of associationsTherapeutics department at assiut universityMonash health rheumatology unitRheumatology researchEuropean allianceAdvanced therapeutics departmentAssiut universitySystemic lupus erythematosusLupus nephritisJak statAk stat signaling pathway

Study Shifts Burden of IgG4-Related Disease to Women

First population-based US study establishes "key benchmarks" for immune-mediated condition initially described in 2001.

United statesZacharys wallaceRheumatology research foundationClinformatics data martMedicare advantageMassachusetts general hospitalNational institutesNational instituteSkin diseasesRheumatology researchIgg4 syndromeMmunoglobulin g4 related diseaseIgg4 related diseaseGg4 rdGg4 related systemic sclerosing diseaseGg4 related sclerosing disease